Skip to content
The Cancer History Project
HOME
ABOUT
THE CANCER HISTORY PROJECT
THE CANCER LETTER
EDITORIAL BOARD
SPONSORS
CONTRIBUTORS
TCL ARCHIVES
LATEST ARTICLES
Search for:
Search
ARCHIVES
NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.
This article is from
The Cancer Letter
archive.
Vol. 33 No. 27 | July 13, 2007
Download PDF
Visit The Full Archive
Related Articles
TCL Archive
ACS Plans 7 Hearings Around U.S. On cancer In The Disadvantaged
April 7, 1989
TCL Archive
Gramm-Rudman Cut Facing NCI Could Take $85 Million
October 20, 1989
TCL Archive
Xeloda As Effective As 5-FU/LV, Five-Year Survival Data Show
September 28, 2007
TCL Archive
Letters: Subcommittee Report Full Of Errors, Gallo Attorney Says
February 3, 1995
TCL Archive
Community Based Organizing Nearly Complete; Conn. Still Planning
November 25, 1977
TCL Archive
Estrogen-Only HRT Little Risk In Endometrial Cancer, GOG Study Indicates
March 26, 2004